药学学报, 2014, 49(12): 1665-1673
引用本文:
李路军, 杨艳群, 胡雪平, 谢冕, 刘梦元. 抗TNF-α/抗ED-B双特异抗体的构建与功能分析[J]. 药学学报, 2014, 49(12): 1665-1673.
LI Lu-jun, YANG Yan-qun, HU Xue-ping, XIE Mian, LIU Meng-yuan. Construction and functional analysis of a bispecific antibody that targets TNF-α and ED-B[J]. Acta Pharmaceutica Sinica, 2014, 49(12): 1665-1673.

抗TNF-α/抗ED-B双特异抗体的构建与功能分析
李路军1,2,3, 杨艳群1,3, 胡雪平1,3, 谢冕1,3, 刘梦元1,3
1. 暨南大学第二临床医学院/深圳市老年医学研究所, 广东 深圳 518020;
2. 湖北大学生命科学学院感染与免疫研究中心, 湖北 武汉 430062;
3. 湖北绿色生物资源转换协同创新中心, 湖北 武汉 430062
摘要:
为了赋予TNF-α抗体对炎症组织的特异性, 构建了抗TNF-α/抗纤维连接蛋白额外域B (ED-B) 的基因工程双特异抗体BsDb.BsDb在大肠杆菌中获得了高效表达, 表达产物经鉴定、纯化和复性制备后, 进行了生物学活性和药动学分析.BsDb可同时结合重组人TNF-α和ED-B, 并中和TNF-α生理作用.在胶原诱导的小鼠关节炎模型中, BsDb快速从血浆和正常组织清除, 但能选择性的积累和保留于炎症关节.说明BsDb具有炎症组织的特异性和正常组织的低毒性, 在类风湿关节炎和其他自身免疫性疾病的治疗上具有较大潜力, 为其临床前期研究奠定了基础.
关键词:    双特异抗体      类风湿关节炎      纤维连接蛋白      肿瘤坏死因子α      额外域B     
Construction and functional analysis of a bispecific antibody that targets TNF-α and ED-B
null
1. The Second Clinical Medical College of Jinan University, Shenzhen Institute of Geriatrics, Shenzhen 518020, China;
2. Center for Infection and Immunity Research, College of Life Sciences, Hubei University, Wuhan 430062, China;
3. Hubei Collaborative Innovation Center for Green Transformation of Bioresources, Wuhan 430062, China
Abstract:
In order to enhance the specificity of TNF-α monoclonal antibody to inflamed site, a bispecific antibody BsDb that targets TNF-α and the extra-domain B (ED-B) of fibronectin (FN) was constructed by covalently linking the anti-TNF-α single chain Fv antibody (TNF-scFv) and the anti-ED-B scFv L19 via a flexible peptide linker deriving from human serum albumin (HSA). ED-B is an antigen specifically expressed at the inflamed site. BsDb is expressed in E. coli, identified by immunoblot, and purified with affinity chromatography. This was followed by further examination of its bioactivities and pharmacokinetics. We demonstrated that BsDb retained the immunoreactivity of its original antibodies as it could simultaneously bind to TNF-α and ED-B and neutralize the biological action of TNF-α. In the collagen-induced arthritis mice model, BsDb selectively accumulate in the inflamed joint with a maximal uptake of (12.2 ± 1.50) % ID/g in a single inflamed paw and retain in the inflamed paw for at least 72 h. In contrast, BsDb showed a short serum half-life of (0.50 ± 0.05) h and a rapid clearance from normal tissues. The findings reported herein indicate that BsDb has good specificity to the inflamed site and low toxicity to normal tissues. BsDb is therefore likely to have greater clinical applications in the treatment of rheumatoid arthritis and other autoimmune diseases. This laid a stable basis for its preclinical study.
Key words:    bispecific antibody    rheumatoid arthritis    fibronectin    tumor necrosis factor α    extro-domain B   
收稿日期: 2014-06-24
基金项目: 国家自然科学基金资助项目(30973669).
通讯作者: 刘梦元
Email: liumengy@tom.com
相关功能
PDF(9473KB) Free
打印本文
0
作者相关文章
李路军  在本刊中的所有文章
杨艳群  在本刊中的所有文章
胡雪平  在本刊中的所有文章
谢冕  在本刊中的所有文章
刘梦元  在本刊中的所有文章

参考文献:
[1] Armuzzi A, Lionetti P, Blandizzi C, et al. Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab [J]. J Immunopathol Pharmacol, 2014, 27 (1 Suppl): 11-32.
[2] Meroni PL, Valesini G. Tumour Necrosis Factor α Antagonists in the Treatment of Rheumatoid Arthritis: An Immunological Perspective [J]. BioDrugs, 2014, 28 (Suppl 1): 5-13.
[3] Papoutsaki M, Costanzo A. Treatment of psoriasis and psoriatic arthritis [J]. BioDrugs, 2013, 27 (Suppl 1): 3-12.
[4] Fiorino G, Danese S, Pariente B, et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents [J]. Autoimmun Rev, 2014, 13: 15-19.
[5] Choy EH, Connolly DJ, Rapson N, et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients [J]. Rheumatology (Oxford), 2000, 39: 1139-1146.
[6] Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease [J]. AAPS J, 2010, 12: 33-43.
[7] Alawneh KM, Ayesh MH, Khassawneh BY, et al. Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis [J]. Biologics, 2014, 8: 193-198.
[8] Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? [J]. Arthritis Rheum, 2009, 60: 3180-3189.
[9] Cuesta AM, Sainz-Pastor N, Bonet J, et al. Multivalent antibodies: when design surpasses evolution [J]. Trends Biotechnol, 2010, 28: 355-362.
[10] Carnemolla B, Balza E, Siri A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors [J]. J Cell Biol, 1989, 108: 1139- 1148.
[11] Galler K, Junker K, Franz M, et al. Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery [J]. Histochem Cell Biol, 2012 137: 195-204.
[12] Ventura E, Sassi F, Parodi A, et al. Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8 [J]. PLoS One, 2010, 5: e9145.
[13] Sauer S, Erba PA, Petrini M, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients [J]. Blood, 2009, 113: 2265-2274.
[14] Castellani P, Viale G, Dorcaratto A, et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis [J]. Int J Cancer, 1994, 59: 612-618.
[15] Mortara L, Orecchia P, Castellani P, et al. Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine [J]. Cancer Med, 2013, 2: 478-487.
[16] Locher R, Erba PA, Hirsch B, et al. Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient [J]. J Cancer Res Clin Oncol, 2014, 140: 35-43.
[17] Poli GL, Bianchi C, Virotta G, et al. Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study [J]. Cancer Immunol Res, 2013, 1: 134-143.
[18] Kriegsmann J, Berndt A, Hansen T, et al. Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis [J]. Rheumatol Int, 2004, 24: 25-33.
[19] Claudepierre P, Allanore Y, Belec L, et al. Increased Ed-B fibronectin plasma levels in spondyloarthropathies: comparison with rheumatoid arthritis patients and a healthy population [J]. Rheumatology (Oxford), 1999, 38: 1099-1103.
[20] Trachsel E, Bootz F, Silacci M, et al. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis [J]. Arthritis Res Ther, 2007, 9: R9. doi: 10.1186/ar2115.
[21] Ventura E, Balza E, Borsi L, et al. Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report [J]. BMC Biotechnol, 2011. doi: 10.1186/1472-6750-11-104.
[22] Vollmer S, Vater A, Licha K, et al. Extra domain B fibronectin as a target for near-infrared fluorescence imaging of rheumatoid arthritis affected joints in vivo [J]. Mol Imaging, 2009, 8: 330-340.
[23] Liu M, Wang X, Yin C, et al. One-step on-column purification and refolding of a single-chain variable fragment (scFv) antibody against tumour necrosis factor alpha [J]. Biotechnol Appl Biochem, 2006, 43 (Pt 3): 137-145.
[24] Liu M, Wang X, Yin C, et al. Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb [J]. Biochem J, 2007, 406: 237-246.
[25] Liu M, Wang X, Yin C, et al. A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumour necrosis factor alpha [J]. Biotechnol Appl Biochem, 2008, 50 (Pt 4): 173-179.
[26] Yoshimura S, Asano K, Nakane A. Attenuation of collagen-induced arthritis in mice by salmon proteoglycan [J]. Biomed Res Int, 2014. doi: 10.1155/2014/406453.
[27] Chang SK, Gu Z, Brenner MB. Fibroblast-like synoviocytes in inflammatory arthritis pathology: the emerging role of cadherin-11 [J]. Immunol Rev, 2010, 233: 256-266.
[28] Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation [J]. Nat Rev Immunol, 2010, 10: 301-316.
[29] Boeggeman EE, Ramakrishnan B, Qasba PK. The N-terminal stem region of bovine and human beta 1, 4-galactosyltransferase I increases the in vitro folding efficiency of their catalytic domain from inclusion bodies [J]. Protein Expr Purif, 2003, 30: 219-229.
[30] Luo D, Mah N, Wishart D, et al. Construction and expression of bi-functional proteins of single-chain Fv with effector domains [J]. J Biochem, 1996, 120: 229-232.
[31] Jafari R, Holm P, Piercecchi M, et al. Construction of divalent anti-keratin 8 single-chain antibodies (sc(Fv)(2)), expression in Pichia pastoris and their reactivity with multicellular tumor spheroids [J]. J Immunol Methods, 2011, 364: 65-76.
[32] Jorgensen ML, Friis NA, Just J, et al. Expression of single-chain variable fragments fused with the Fc-region of rabbit IgG in Leishmania tarentolae [J]. Microb Cell Fact, 2014. doi: 10.1186/1475-2859-13-9.
[33] Caravella J, Lugovskoy A. Design of next-generation protein therapeutics [J]. Curr Opin Chem Biol, 2010, 14: 520-528.
相关文献:
1.李清萃, 韩晓辉, 周兵, 王文飞, 任桂萍, 孙翠羽, 吴强, 于引航, 徐黎明, 王秋颖, 齐剑英, 魏雨泉, 曹宏伟, 韩俊岩, 李德山.三种双特异性抗体对小鼠类风湿关节炎模型的治疗效果[J]. 药学学报, 2014,49(3): 322-328